Evidence map›Paper›PMID 40583436›Full record

ReviewAdvanced healthcare materials2025

Immunomodulatory Delivery Materials for Tissue Repair.

Savannah Est-Witte, Manav Jain, Elana Ben-Akiva, Joanna Yang, Tiarra Warren, Stephany Y Tzeng, Jordan J Green

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Savannah Est-WitteDepartment of Biomedical Engineering, Institute for NanoBioTechnology, Translational Tissue Engineering Center, and the Johns Hopkins Translational Immunoengineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Manav JainDepartment of Biomedical Engineering, Institute for NanoBioTechnology, Translational Tissue Engineering Center, and the Johns Hopkins Translational Immunoengineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Elana Ben-AkivaDepartment of Biomedical Engineering, Institute for NanoBioTechnology, Translational Tissue Engineering Center, and the Johns Hopkins Translational Immunoengineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Joanna YangDepartment of Biomedical Engineering, Institute for NanoBioTechnology, Translational Tissue Engineering Center, and the Johns Hopkins Translational Immunoengineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Tiarra WarrenDepartment of Biomedical Engineering, Institute for NanoBioTechnology, Translational Tissue Engineering Center, and the Johns Hopkins Translational Immunoengineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Stephany Y TzengDepartment of Biomedical Engineering, Institute for NanoBioTechnology, Translational Tissue Engineering Center, and the Johns Hopkins Translational Immunoengineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Jordan J GreenDepartment of Biomedical Engineering, Institute for NanoBioTechnology, Translational Tissue Engineering Center, and the Johns Hopkins Translational Immunoengineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.ORCID https://orcid.org/0000-0003-4176-3808

Funding

TR&D Project 3P41EB028239 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI Jamie Berta Spangler · 2019 to 2026
$11.5M
A PLATFORM TECHNOLOGY TO GENETICALLY REPROGRAM CANCER CELLS FOR ENHANCED IMMUNOTHERAPYR37CA246699 · NCI · JOHNS HOPKINS UNIVERSITY · PI TZENG, STEPHANY YI · 2020 to 2025
$2.6M
Gene Delivery Nanoparticles to Treat GlioblastomaR01CA228133 · NCI · JOHNS HOPKINS UNIVERSITY · PI GREEN, JORDAN · 2019 to 2023
$1.9M
Non-viral nucleic acid delivery to antigen presenting cells for cancer immunotherapyF31CA250367 · NCI · JOHNS HOPKINS UNIVERSITY · PI BEN-AKIVA, ELANA · 2020 to 2021
$85k
National Science Foundation DGE-1746891NCI NIH HHS F31 CA250367NCI NIH HHS R01 CA228133NCI NIH HHS R37 CA246699NIBIB NIH HHS P41 EB028239NIH HHS F31CA250367NIH HHS P41EB028239NIH HHS R01CA228133NIH HHS R37CA246699
6 · The paper itself

Abstract

The immune system plays a critical role in the efficacy of regenerative medicine biotechnology, often mediated by delivery biomaterials. In this review, materials design approaches and challenges for the delivery of biomaterial platforms to endogenous cells and tissues to control their function are discussed. These delivery biomaterials can recruit and direct the phenotypes of cells including macrophages, T cells, and mesenchymal stem cells. Key considerations regarding the relevant cell types for tissue engineering and how biomaterials can be used to engineer the optimal immune microenvironment for tissue regeneration are described. The major classes of biomaterial delivery strategies utilized for immunomodulation in the context of tissue repair -scaffold-, cell-, and particle-mediated delivery- are reviewed along with how to utilize them to aid in tissue regeneration.

Indexed as

Biocompatible MaterialsDrug Delivery SystemsImmunomodulationTissue EngineeringAnimalsHumansMesenchymal Stem CellsRegenerative MedicineTissue ScaffoldsBiocompatible Materialsbiomaterialsimmunomodulationnanoparticlesregenerative medicinescaffolds

Identifiers

PMID40583436
PMCPMC12365890

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.